The Motley Fool estimates Eli Lilly’s unapproved retatrutide could be worth more than $10 billion to the company, citing Phase 3 weight-loss results and potential use in severe obesity; Lilly plans to submit an approval application in the first quarter of 2027.
Retatrutide mimics GLP-1, GIP and glucagon. One Phase 3 study reported average weight loss of 28.3% over 80 weeks among people with obesity; another reported 20.8% among overweight or obese participants with diabetes. Lilly has also reported positive Phase 3 results in patients with obesity and sleep apnea or knee osteoarthritis pain.
Some analysts project peak annual sales of up to $25 billion. The article argues retatrutide could serve people with treatment-resistant obesity and help Lilly retain patients who might otherwise switch to competitors, though it could also take sales from Lilly’s tirzepatide. Retatrutide remains unapproved, and ongoing studies could encounter setbacks.
